Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATHE 
Alterity Therapeutics Ltd (ATHE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ATHE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.42% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 67.61M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 3 | Beta 0.05 | 52 Weeks Range 1.00 - 7.00 | Updated Date 11/4/2025 |
52 Weeks Range 1.00 - 7.00 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -223.35% | Operating Margin (TTM) -185.73% |
Management Effectiveness
Return on Assets (TTM) -28.09% | Return on Equity (TTM) -43.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45149390 | Price to Sales(TTM) 12.43 |
Enterprise Value 45149390 | Price to Sales(TTM) 12.43 | ||
Enterprise Value to Revenue 113.99 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 18125694 | Shares Floating 6967524172 |
Shares Outstanding 18125694 | Shares Floating 6967524172 | ||
Percent Insiders - | Percent Institutions 2.37 |
Upturn AI SWOT
Alterity Therapeutics Ltd
Company Overview
History and Background
Alterity Therapeutics Ltd, formerly Prana Biotechnology, focuses on developing therapies for neurodegenerative diseases. Founded to target neurodegenerative diseases with a focus on iron mismanagement, it has shifted its focus and pipelines over time to address unmet needs in specific diseases.
Core Business Areas
- Drug Development: Developing novel therapies for neurodegenerative diseases, particularly those involving iron mis-management.
Leadership and Structure
Led by a management team with experience in pharmaceutical development and neuroscience. Organisational structure typical of a small biotech company with research, clinical and business development functions.
Top Products and Market Share
Key Offerings
- ATH434: Lead product candidate, ATH434, an investigational treatment for Multiple System Atrophy (MSA). Currently in clinical development (Phase 2). Competitors include companies developing therapies for MSA, but there are currently no approved therapies for this specific disease. Market share is currently 0 as not yet approved. Primary competitors will emerge as other companies develop MSA therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the neurodegenerative disease therapeutic area, is characterized by high unmet need and significant research and development investment. Development is slow due to the nature of the disease.
Positioning
Alterity Therapeutics is positioned as a company focused on developing novel therapies for neurodegenerative diseases. Its competitive advantage, if any, lies in the novelty and efficacy of its lead drug candidate, ATH434.
Total Addressable Market (TAM)
The global market for neurodegenerative disease therapeutics is substantial. The MSA portion of the TAM is estimated to be over $1 Billion USD. Alterity is positioned to address a portion of this TAM if ATH434 proves to be efficacious and safe.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (ATH434)
- Focus on unmet medical needs (MSA)
- Experienced management team
- Orphan Drug Designation by FDA
Weaknesses
- Limited financial resources
- Single lead product candidate (ATH434)
- Clinical trial risks
- Reliance on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline
- Positive clinical trial results
- Breakthrough therapy designation
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies
- Patent challenges
Competitors and Market Share
Key Competitors
- Not enough information to display competitors
Competitive Landscape
Alterity Therapeutics faces competition from other biotechnology and pharmaceutical companies developing therapies for neurodegenerative diseases. The company's competitive advantage depends on the novelty and efficacy of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to its development-stage status.
Future Projections: Future growth is dependent on the successful development and commercialization of ATH434, which is subject to uncertainty. Analyst estimates depend on clinical trial data and regulatory approvals.
Recent Initiatives: Advancing ATH434 through Phase 2 clinical trials. Seeking partnerships and funding to support development programs.
Summary
Alterity Therapeutics is a high-risk, high-reward biotechnology company focused on developing therapies for neurodegenerative diseases. Its future success hinges on the positive results of clinical trials for its lead drug candidate, ATH434. The company's limited financial resources and reliance on a single product candidate are key risks to consider. Positive clinical data could drive significant value creation, while setbacks could have a negative impact.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investing in biotechnology companies carries significant risk, including the risk of loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alterity Therapeutics Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2002-09-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://alteritytherapeutics.com |
Full time employees 9 | Website https://alteritytherapeutics.com | ||
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.